SLE Mouse Model
Mouse models have contributed to significant progress in uncovering mechanisms by which lupus develops and sustains disease conditions and in evaluations of therapeutic efficacy. Pristane-induced lupus is a well-established model of murine lupus. Disease development following injection of pristane in a variety of mouse strains leads to an inflammatory process resulting in lupus-specific autoantibodies, immune complex deposition resulting in a variety of organ manifestations with a high prevalence of nephritis.
The purpose of this in vivo study is to provide information for development of human therapeutic products for treatment of lupus disease. There is no in vitro model available to develop the information. An animal model is very popular for the study of lupus to obtain the systemic information with the characteristics of the human SLE.
The animal model selected and the animal species is based on studies in the scientific literature indicating the usefulness of this model for development of drugs for treatment of human disease.
| SLE Mouse Model | |
| A well-established model of murine lupus | |
| Species |
Balb/c mice, 7-9 week old, female |
| Group Size | 10 |
| Study Duration | 3-6 months |
| Read-outs |
Observations and body weight once a week, Anti-dsDNA, ANA (titer and photos), Serum Cytokines (TNF a, IL-beta, IL-17) |
| Optional |
Kidney tissue histopathology (the severity of the renal lesion) Glomerulonephritis, renal tubular lesions and interstitial inflammation observed Immunohistochemistry: IgG and complement C3c in the glomeruli anti-snRNP/Sm (small nuclear ribonucleoproteins) Anti-chromatin autoantibody Histone Antibodies Other Cytokines as requested |
Comparison of autoantibody (anti-ds DNA lgG) with PBS (group 1), pristane/vehicle (group 2), prednisone (group 3) and test compound (group 4) treatment
Antinuclear antibodies in the sera of control (PBS), pristane-treated, prednisone and test compound treatment mice at week 12 (top) and week 20 (below) after pristane injection were determined by immunofluorescence staining on HEp-2 cells (IFA photos, 1:40 serum dilution)
WEEK 12
WEEK 20
